OPT vs. CGEN, ELEV, ZURA, ABOS, INMB, XFOR, KOD, IPHA, GNFT, and ADVM
Should you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Compugen (CGEN), Elevation Oncology (ELEV), Zura Bio (ZURA), Acumen Pharmaceuticals (ABOS), INmune Bio (INMB), X4 Pharmaceuticals (XFOR), Kodiak Sciences (KOD), Innate Pharma (IPHA), Genfit (GNFT), and Adverum Biotechnologies (ADVM). These companies are all part of the "biological products, except diagnostic" industry.
Opthea (NASDAQ:OPT) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Opthea has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.
Compugen received 288 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 64.33% of users gave Compugen an outperform vote while only 50.00% of users gave Opthea an outperform vote.
In the previous week, Compugen had 8 more articles in the media than Opthea. MarketBeat recorded 8 mentions for Compugen and 0 mentions for Opthea. Opthea's average media sentiment score of 0.40 beat Compugen's score of 0.25 indicating that Opthea is being referred to more favorably in the media.
Opthea currently has a consensus price target of $14.00, indicating a potential upside of 315.43%. Compugen has a consensus price target of $4.00, indicating a potential upside of 123.46%. Given Opthea's higher probable upside, research analysts clearly believe Opthea is more favorable than Compugen.
56.0% of Opthea shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Opthea's return on equity of 0.00% beat Compugen's return on equity.
Compugen has higher revenue and earnings than Opthea.
Summary
Compugen beats Opthea on 7 of the 13 factors compared between the two stocks.
Get Opthea News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
